Back to Search Start Over

NCCN guideline–concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.

Authors :
Mezger, Nikolaus Christian Simon
Seraphin, Tobias Paul
Ballé, Robert
Griesel, Mirko
Joko-Fru, Yvonne Walburga
Hämmerl, Lucia
Feuchtner, Jana
Liu, Biying
Zietsman, Annelle
Kamaté, Bakarou
Gnangnon, Freddy Houéhanou Rodrigue
Gnahatin, Franck
Mboungou, Dimitry Moudiongui
Assefa, Mathewos
Amulen, Phoebe Mary
Chesumbai, Gladys
Chingonzoh, Tatenda
Lorenzoni, Cesaltina Feirreira
Korir, Anne
Santos, Pablo S Carvalho
Source :
JNCI: Journal of the National Cancer Institute. Jan2025, Vol. 117 Issue 1, p120-133. 14p.
Publication Year :
2025

Abstract

Background To assess population-based quality of cancer care in sub-Saharan Africa and to identify specific gaps and joint opportunities, we assessed concordance of diagnostics and treatments with National Comprehensive Cancer Network Harmonized Guidelines for leading cancer types in 10 countries. Methods Adult patients with female breast cancer, cervical cancer, colorectal cancer, non-Hodgkin lymphoma, and prostate cancer were randomly drawn from 11 population-based cancer registries. Guideline concordance of diagnostics and treatment was assessed using clinical records. In a subcohort of 906 patients with potentially curable cancer (stage I-III breast cancer, cervical cancer, colorectal cancer, prostate cancer, aggressive non-Hodgkin lymphoma [any stage]) and documentation for more than 1 month after diagnosis, we estimated factors associated with guideline-concordant treatment or minor deviations. Results Diagnostic information based on guidelines was complete for 1030 (31.7%) of a total of 3246 patients included. In the subcohort with curable cancer, guideline-concordant treatment was documented in 374 (41.3%, corresponding to 11.7% of 3246 patients included in the population-based cohort): aggressive non-Hodgkin lymphoma (59.8%/9.1% population based), breast cancer (54.5%/19.0%), prostate cancer (39.0%/6.1%), colorectal cancer (33.9%/9.5%), and cervical cancer (27.8%/11.6%). Guideline-concordant treatment was most frequent in Namibia (73.1% of the curable cancer subcohort/32.8% population based) and lowest in Kampala, Uganda (13.5%/3.1%). Guideline-concordant treatment was negatively associated with poor ECOG-ACRIN performance status, locally advanced disease stage, origin from low Human Development Index countries, and a diagnosis of colorectal cancer or cervical cancer. Conclusions The quality of diagnostic workup and treatment showed major deficits, with considerable disparities among countries and cancer types. Improved diagnostic services are necessary to increase the share of curable cancer in sub-Saharan Africa. Treatment components within National Comprehensive Cancer Network Guidelines for several cancers should be prioritized. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00278874
Volume :
117
Issue :
1
Database :
Academic Search Index
Journal :
JNCI: Journal of the National Cancer Institute
Publication Type :
Academic Journal
Accession number :
182214648
Full Text :
https://doi.org/10.1093/jnci/djae221